溃疡性结肠炎的分期治疗

刘润利; 刘力; 周铖; 杜晓泉

doi:10.3969/j.issn.1671-038X.2021.01.15

溃疡性结肠炎的分期治疗

- 1 陕西中医药大学第一临床医学院中医系(陕西咸阳, 712000);
- 2 陕西中医药大学;
- 3 陕西中医药大学第一附属医院消化二科

详细信息

通讯作者: 刘力,E-mail:liuyan791@163.com

中图分类号: R574.62

收稿日期: 2020-09-26

Stage treatment of ulcerative colitis

More Information

Corresponding author: LIU Li, E-mail: liuyan791@163.com

Received Date: 26 September 2020

摘要

- 溃疡性结肠炎 /
- 微生态制剂 /
- 粪菌移植 /
- 治疗
Abstract: Ulcerative colitis(UC) is a chronic inflammatory disease occurring in the intestine, mainly manifested as recurrent abdominal pain, diarrhea and mucous pus, blood and stool. The treatment includes conventional anti-inflammatory treatment in internal medicine, surgical operation, and high fever of microecological agents and fecal microbiota transplantation in recent years. UC can be divided into remission phase and active phase clinically. According to the different severity, UC can be mild, moderate or severe in active phase. It is particularly important to determine the severity of UC for the selection of appropriate treatment methods. This article reviews the treatment of ulcerative colitis in different periods and degrees.
- ulcerative colitis /
- microecological agents /
- fecal bacteria transplantation /
- treatment

HTML全文

参考文献(37)

[1]	Mavroudis G,Magnusson MK,Isaksson S,et al.Mucosal and systemic immune profiles differ during early and late phases of the disease in patients with active ulcerative colitis[J].J Crohns Colitis,2019,13(11):1450-1458.
[2]	Tun X,Yasukawa K,Yamada KI.Nitric oxide is involved in activation of Toll-like receptor 4 signaling through tyrosine nitration of src homology protein tyrosine phosphatase 2 in murine dextran sulfate-induced colitis[J].Biol Pharm Bull,2018,41(12):1843-1852.
[3]	Khan I,Ullah N,Lajia Z,et al.Alteration of Gut Microbiota in Inflammatory Bowel Disease(IBD):Cause or Consequence?IBD Treatment Targeting the Gut Microbiome Pathogens[J].Pathogens,2019,8(3):126-127.
[4]	Antonelli E,Villanacci V,Bassotti G.Novel oral-targeted therapies for mucosal healing in ulcerative colitis[J].World J Gastroenterol,2018,24(47):5322-5330.
[5]	Klotz C,Barret M,Dhooge M,et al.Management of Diagnosis and Treatment in Ulcerative Colitis[J].Presse Med,2015,44(2):144-149.
[6]	Lobatón T,Bessissow T,Hertogh GD,et al.The Modified Mayo Endoscopic Score(MMES):A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis[J].J Crohn Colitis,2015,9(10):846-852.
[7]	吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中国实用内科杂志,2018,38(9):796-813.
[8]	Lamb CA,Kennedy NA,Raine T,et al.British Society of Gastroenterology Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults[J].Gut,2019,68(Suppl 3):s1-s106.
[9]	Nguyen NH,Fumery M,Dulai PS,et al.Comparative Efficacy and Tolerability of Pharmacological Agents for Management of Mild to Moderate Ulcerative Colitis:A Systematic Review and Network Meta-Analyses[J].Lancet Gastroenterol Hepatol,2018,3(11):742-753.
[10]	Feagan BG,Chande N,MacDonald JK.Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis?Evidence from cochrane reviews[J].Inflamm Bowel Dis,2013,19(9):2031-2040.
[11]	Bressler B,Marshall JK,Bernstein CN,et al.Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis:the Toronto consensus[J].Gastroenterology,2015,148(5):1035-1058.
[12]	Ungaro R,Mehandru S,Allen PB,et al.Ulcerative Colitis[J].Lancet,2017,389(10080):1756-1770.
[13]	Danese S,Jee RB,Fraser Cummings JR,et al.Consensus Recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis:the i Support Therapy-Access to Rapid Treatment(iSTART)approach[J].Intest Res,2018,16(4):522-528.
[14]	Cynthia WK,Singh S,Feuerstein JD.AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis[J].Gastroenterology,2019,156(3):748-776.
[15]	Bressler B,Marshall JK,Bernstein CN,et al.Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis:the Toronto consensus[J].Gastroenterology,2015,148(5):1035-1058.
[16]	Rubin DT,Cohen RD,Sandborn WJ,et al.Budesonide Multimatrix Is Efficacious for Mesalamine-refractory,Mild to Moderate Ulcerative Colitis:A Randomised,Placebo-controlled Trial[J].J Crohns Colitis,2017,11(7):785-791.
[17]	张国兴,石荣.溃疡性结肠炎治疗进展[J].现代中西医结合杂志,2019,28(25):2842-2847.
[18]	Gert VA,Geert D,Maja N,et al.Randomized,double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis[J].Gastroenterology,2003,125(4):1025-1031.
[19]	冯锦霞,夏忠胜.溃疡性结肠炎的非手术治疗进展[J].新医学,2019,50(1):1-6.
[20]	Fumi V,Konstantinos A,Frank P,et al.Profile of Tofacitinib in the Treatment of Ulcerative Colitis:An Evidence-Based Review of Recent Data[J].Drug Des Dev Ther,2019,13:4091-4105.
[21]	Bonovas S,Lytras T,Nikolopoulos G,et al.Systematic review with network meta-analysis:comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis[J].Aliment Pharmacol Ther,2018,47(4):454-465.
[22]	Singh S,Fumery M,Sandborn WJ,et al.Systematic review with network metaanalysis:first-and second-line pharmacotherapy for moderate-severe ulcerative colitis[J].Aliment Pharmacol Ther,2018,47(2):162-175.
[23]	Hernández-Rocha C,Ibáňez P,Molina ME,et al.Management of severe ulcerative colitis:An up-to-date[J].Revista medica de Chile,2017,145(1):75-84.
[24]	Laharie D,Bourreille A,Branche J,et al.Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids:a parallel,open-abel randomised controlled trial[J].Lancet,2012,380 (9857):1909-1915.
[25]	Peyrin-Biroulet L,Germain A,Patel AS,et al.Systematic review:outcomes and post-operative complications following colectomy for ulcerative colitis[J].Aliment Pharmacol Ther,2016,44(8):807-816.
[26]	Adams SM,Bornemann PH.Ulcerative Colitis[J].Am Fam Physician,2013,87(10):699-705.
[27]	周铖,孙鹏飞,尹继瑶,等.粪菌移植治疗炎症性肠病的研究进展[J].上海交通大学学报(医学版),2020,40(2):267-270.
[28]	史佳鹭,闫芬芬,李慧臻,等.益生菌对溃疡性结肠炎影响的研究进展[J].食品科学,2020,41(15):301-308.
[29]	Khan I,Ullah N,Zha L,et al.Alteration of Gut Microbiota in Inflammatory Bowel Disease(IBD):Cause or Consequence?IBD Treatment Targeting the Gut Microbiome[J].Pathogens,2019,8(3).126-128.
[30]	黄月莹,戴迟兵.粪菌移植治疗溃疡性结肠炎的研究进展[J].心理月刊,2020,15(2):238-240.
[31]	Eiseman B,Silen W,Bascom GS,et al.Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis[J].Surgery,1958,44(5):854-859
[32]	Anderson JL,Edney RJ,Whelan K.Systematic review:faecal microbiota transplantation in the management of inflammatory bowel disease[J].Aliment Pharmacol Ther,2012,36(6):503-516.
[33]	Kunde S,Pham A,Bonczyk S,et al.Safety,tolerability,and clinical response after fecal transplantation in children and young adults with ulcerative colitis[J].J Pediatr Gastr Nutr,2013,56(6):597-601.
[34]	Angelberger S,Reinisch W,Makristathis A,et al.Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation[J].Am J Gastroenterol,2013,108(10):1620-1630.
[35]	Kump PK,Grochenig HP,Lackner S,et al.Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis[J].Inflamm Bowel Dis,2013,19(10):2155-2165.
[36]	Berg D,Clemente JC,Colombel JF.Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome[J]?Expert Rev Gastroenterol Hepatol,2015,9(6):781-795.
[37]	Ko CW,Singh S,Feuerstein JD,et al.AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis[J].Gastroenterology,2019,156(3):748-764.